MedTrace Logo

A Study to Evaluate the Drug Levels of Cendakimab Delivered Subcutaneously in Healthy Participants

NCT05337345 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2023-02-10

No results posted yet for this study

Summary

The purpose of this study is to evaluate the drug levels of cendakimab delivered subcutaneously in healthy participants.

Conditions

  • Healthy Volunteers

Interventions

DRUG

Cendakimab

Specified Dose on Specified Days

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-05-02
Primary Completion
2022-12-15
Completion
2022-12-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05337345 on ClinicalTrials.gov